NEW YORK, Sept. 08, 2017 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Rayonier Advanced Materials Inc. (NYSE:RYAM) from October 29, 2014 through August 19, 2015, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Rayonier investors under the federal securities laws.
To join the Rayonier class action, go to http://rosenlegal.com/cases-1196.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that since 2013, one of its top three customers, Eastman Chemical Company, had been informing Rayonier of its competitors’ pricing and had requested that Rayonier respond to declines in market pricing, leading to a protracted dispute between Rayonier and Eastman over the “meet and release” provision of their agreement. Nevertheless, Rayonier claimed during the Class Period that in 2015 Rayonier “will be able to maintain or increase [its] share of volume at each of [its] top 10 customers.” When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 16, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1196.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com


John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 



